What an FDA Leadership Change Could Mean for Fertility Patients

If you're in the middle of a cycle, the last thing you want to read is another headline about federal agencies. You have enough to track: trigger timing, monitoring appointments, the pharmacy that may or may not have your meds in stock this week.

But a story is moving in Washington that's worth a few minutes of your attention — not because anything has changed for your protocol today, but because the people who decide what's available at your pharmacy may be about to change.

FDA Commissioner Marty Makary is reportedly planning to step down, and anti-abortion groups are pushing for a successor who would tighten access to mifepristone — the medication used in medication abortion and miscarriage management.¹ The immediate fight is about abortion access. But the FDA is the same agency that approves and regulates every medication used in IVF, IUI, and fertility preservation. So it's reasonable to ask: could a more restrictive posture at the top of the agency ripple into fertility care?

The honest answer is: probably not in the short term, and not in the dramatic ways social media will suggest. But there are a few things worth understanding so you can read the next round of headlines without panic.

What the FDA actually controls in your cycle

Almost every drug in a standard fertility protocol is FDA-approved and has been for years or decades. Gonadotropins, GnRH agonists and antagonists, hCG triggers, progesterone in its various forms, estradiol — these are long-established medications. The FDA's role is approving new drugs, monitoring safety, regulating manufacturing, and overseeing labeling (including what a drug is officially approved to treat).

What the FDA does not do: tell your clinic how to practice medicine, decide whether IVF is legal, or set the price of your meds.

That distinction matters, because when people hear "FDA shake-up," they often imagine a commissioner could wake up tomorrow and pull fertility drugs off shelves. That's not how the agency works. Approvals are hard to unwind, and the medications used in fertility care don't carry the political charge that mifepristone does.

Where a leadership change could actually matter

A few areas are worth watching — not as predictions, but as the places where a shift in priorities at the top could be felt downstream:

Mifepristone access for miscarriage management. This is the most direct overlap with fertility patients. Mifepristone, paired with misoprostol, is one of the standard, evidence-based options for managing an early pregnancy loss at home. If access tightens — through label changes, distribution restrictions, or pharmacy rules — people experiencing miscarriage could lose a meaningful option, even in states where abortion is otherwise legal.¹ If you've ever been told "you have a few options for how to manage this," that menu could get shorter.

Off-label use. A lot of reproductive medicine happens off-label, meaning a drug is FDA-approved for one purpose but routinely used for another based on clinical evidence. Letrozole for ovulation induction is the classic example — it's approved as a breast cancer drug. Off-label prescribing is legal and standard, but a more activist FDA can influence the climate around it through labeling changes, warning letters, or guidance documents.

Manufacturing and supply. The FDA regulates the facilities that make your meds. Shortages of fertility drugs have happened before, often for boring reasons (a manufacturing inspection, a supply chain issue). Leadership priorities can shape how quickly the agency responds when supply tightens.

New approvals. A more cautious or politically attuned FDA can slow-walk approvals for new reproductive technologies, new formulations, or expanded indications. You won't notice this in a single cycle, but over years it shapes what's on the menu.

What is not likely to happen

It's worth being equally clear about what a commissioner change does not mean:

• IVF itself is not regulated into existence by the FDA. The procedure is governed by a mix of state law, professional standards, and CLIA lab regulations. A commissioner cannot ban IVF.
• Your current protocol is not going to be pulled mid-cycle.
• The drugs in your fridge right now are not suddenly unsafe or unapproved.

The risk is slower and quieter than that — a tightening climate, not a cliff.

What to actually do with this information

If you're a person who finds it grounding to be informed, here's a practical version of "staying informed" that won't eat your week:

1. Ask your clinic, not the internet. If you're starting a cycle in the next few months and you're worried about a specific medication, ask your nurse coordinator: "Has there been any change in availability or sourcing for [drug]?" They know before the news does.

2. If you're managing a loss, know your options now. If you're currently pregnant or trying, it's worth understanding — before you need it — what miscarriage management options your clinic and state currently offer. Not because anything has changed, but because the landscape has been shifting and "what are my choices" is a fair question to ask at any appointment.

3. Keep a small buffer if you can. If your clinic allows it and your insurance permits, don't run your medication supply down to zero between cycles. This is good practice regardless of who runs the FDA.

4. Watch for shortages, not headlines. The most useful early warning sign of any real-world impact isn't a press conference — it's your pharmacy telling you a med is on backorder. If that happens, your clinic almost always has a workaround.

The bigger feeling underneath

There's something exhausting about doing fertility treatment in a political moment where reproductive medicine keeps showing up in the news. You did not sign up for a policy education. You signed up to try to have a baby.

It's okay to opt out of the noise. It's also okay to want to understand the system you're moving through, because feeling informed is sometimes the only form of control available in a process where so little is controllable.

The FDA will have a new commissioner eventually. Your cycle, your protocol, your odds — those are still being shaped, day to day, by your clinical team and your own body. That's where your attention is best spent. The rest, we'll keep watching for you.